EUVIMEDEUVIMED entdecken
Editorial

Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From Europe

Jens Grueger, Kristi Martin, Sean D Sullivan

Value in Health · 2025-09 · 28 (9) · 1305-1308

DOI: 10.1016/j.jval.2025.06.010 ↗

Kurz gefasst

Editorial in der Zeitschrift Value in Health, 2025-09. Verfasst von Jens Grueger und 2 weiteren Autor:innen. Beteiligte Einrichtung: CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA. Electronic address: gruegje1@uw.edu. Hauptthemen laut MEDLINE: Drug Costs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Trump Administration issued an Executive Order on May 12, 2025, with the intent to "equalize pricing across developed countries" through a "Most-Favored Nation" approach with international reference pricing (IRP). IRP has been used extensively in Europe and resulted in short-term budget savings. However, list prices quickly converged to those of major high-income markets, such as Germany and France, without evidence of reduced prices. Despite frequent use of confidential price agreements to differentiate net prices in countries that cannot afford those price levels, access to innovative medicines has been delayed and reduced. This suggests that introduction of IRP in the United States could further limit access in designated reference countries, without sustainable reductions in US price levels. Instead of referencing prices from other countries, the United States should establish its own system for value assessment of medicines, whether at the time of launch or after drugs have been on the market for several years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug CostsUnited StatesEuropeHumansDrug IndustryCommerceCosts and Cost Analysis

Stichwörter der Autor:innen

drug price negotiationsinternational reference pricingmost-favored nationvalue assessment

Autor:innen und Institutionen

  • CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA. Electronic address: gruegje1@uw.edu.
  • Camber Collective, Washington, DC, USA.
  • CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA; Department of Health Policy, London School of Economics and Political Science, London, England, UK.

Zitieren

APA

Grueger, J., Martin, K., & Sullivan, S. D. (2025). Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From Europe. Value in Health, 28(9), 1305-1308. https://doi.org/10.1016/j.jval.2025.06.010

Vancouver

Grueger J, Martin K, Sullivan SD. Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From Europe. Value in Health. 2025;28(9):1305-1308. doi:10.1016/j.jval.2025.06.010

BibTeX
@article{Grueger2025,
  author = {Grueger, Jens and Martin, Kristi and Sullivan, Sean D},
  title = {Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From Europe},
  journal = {Value in Health},
  year = {2025},
  volume = {28},
  number = {9},
  pages = {1305--1308},
  doi = {10.1016/j.jval.2025.06.010}
}
Kostenlos starten →